2445499-20-5

2445499-20-5 structure
2445499-20-5 structure
  • Name: JAK-IN-21
  • Chemical Name: JAK-IN-21
  • CAS Number: 2445499-20-5
  • Molecular Formula: C19H16N8O
  • Molecular Weight: 372.38
  • Catalog: Signaling Pathways Epigenetics JAK
  • Create Date: 2022-11-21 13:15:22
  • Modify Date: 2024-01-29 19:00:46
  • JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively[1].

Name JAK-IN-21
Description JAK-IN-21 (Example 4) is a selective and potent JAK inhibitor with IC50s of 1.73, 2.04, 109 and 62.9 nM against JAK1, JAK2, J2V617F and TYK2, respectively[1].
Related Catalog
Target

JAK1:1.73 nM (IC50)

JAK2:2.04 nM (IC50)

Tyk2:62.9 nM (IC50)

JAK2-V617F:109 nM (IC50)

In Vitro JAK-IN-21 (Example 4) doses not inhibit CYPs and shows good liver microsome stability[1].
In Vivo JAK-IN-21 (Example 4) shows low bioavailability (F=1.9%)[1]. Animal Model: SD rats[1] Dosage: 10 mg/kg Administration: Oral gavage (Pharmacokinetic Study) Result: Rat Colon Pharmacokinetic Study[1] Compound Plasma Cmax (ng/mL) Plasma AUC (h*ng/mL) t1/2 (h) Colon AUC (h*ng/g) Colon + Feces AUC (h*ng/g) JAK-IN-21 68.8 96 1.6 6,623 545,501 Animal Model: SD rats[1] Dosage: 1 mg/kg or 2 mg/kg Administration: Intravenous injection (1 mg/kg) or oral gavage (2 mg/kg) (Pharmacokinetic Study) Result: Pharmacokinetic Parameters in Sprague-Dawley Rats by Intravenous Administration and Oral Administration[1] Compound Dose (mg/kg) AUC (h*ng/mL) T1/2 (h) Cl (mL/min/kg) Vd (L/kg) Cmax (ng/mL) F (%) JAK-IN-21 (iv) 1 854.8 0.22 19.4 0.37 JAK-IN-21 (ig) 2 29.8 0.38 40.4 1.9
References

[1]. Zhaokui WAN, et al. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof. Patent WO2020119819.

Molecular Formula C19H16N8O
Molecular Weight 372.38
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.